BioNTech's Founders Map a Breakaway Venture as German Plants Face the Axe

BioNTech founders plan a new company, Arife SE, as the biotech confirms three German site closures affecting around 1,800 staff.

Two of BioNTech's scientific figureheads are preparing to build something of their own. Plans are taking shape for a new entity called Arife SE, a standalone company that is explicitly not a BioNTech project — yet its creation carries real weight for the Mainz biotech hub the founders helped put on the map.

The split has not been frictionless. According to the report, tensions between the parties ran high ahead of the transition, with patents, future financing and the transfer of staff all emerging as sticking points. Back at BioNTech itself, the looming departure of both scientific masterminds leaves open questions about who steers the company next.

Three German Sites on the Chopping Block

Word of the founders' exit lands alongside a sweeping overhaul of BioNTech's production map. The company confirmed it will close three German locations after efforts to find a buyer fell through. Tübingen, Marburg and Idar-Oberstein are all affected, with the shutdowns staggered over time: Tübingen at the end of 2027, Marburg in early 2028 and Idar-Oberstein at the close of 2028.

Roughly 1,800 employees across the three sites are caught up in the plans, with about 440 of them based at Idar-Oberstein alone. The absence of any external takers for the plants sharpens the blow, and the loss of entire sites marks the end of an expansion push from earlier years. For the domestic manufacturing landscape, it amounts to a substantial rupture.

Patents, Courts and a Leadership Sell-Down

Legal battles are piling on top of the operational cuts. A federal court rejected motions from BioNTech, partner Pfizer and Moderna seeking dismissal of suits brought by Bayer subsidiary Monsanto. The dispute centers on the use of patented mRNA technology in the COVID-19 vaccines the companies produced. The ruling stops short of finding any infringement — it simply allows the litigation to proceed.

Transactions have also been reported from the executive floor. CEO Ugur Sahin parted with further ordinary shares in the biotech group. The sales were executed under a preset trading plan pursuant to Rule 10b5-1, established on 3 June 2026. Such arrangements exist to carry out insider securities transactions on pre-agreed parameters, keeping conflicts of interest around inside information at bay.

A Company in Transition

All of this unfolds against a broader reshaping of BioNTech's business as the pandemic-era windfall fades. Production is being reorganized, intellectual property fights remain live, and scheduled share disposals by management continue on plan.

Investors are watching closely to see which research programs and patents stay inside the group over the long haul, with an orderly handover seen as vital to operational stability. The stock closed Friday at EUR 86.10. Since the start of the year, that leaves the shares up 5.8 percent — a market that, for now, is holding its breath.